Retrospective analyses of the outcomes among hospitalized liver cirrhosis patients with heart failure and COVID-19 infection: Insight from the National Inpatient Sample.
COVID-19
Heart failure
Liver cirrhosis
Journal
American heart journal plus : cardiology research and practice
ISSN: 2666-6022
Titre abrégé: Am Heart J Plus
Pays: United States
ID NLM: 101779333
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
23
12
2022
revised:
04
02
2023
accepted:
04
02
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
ppublish
Résumé
There is paucity of data regarding the impact of Coronavirus Disease 2019 (COVID-19) infection on the outcomes of hospitalized liver cirrhosis (LC) patients with heart failure (HF). Utilizing the 2020 National Inpatient Sample (NIS) Database, we conducted a retrospective cohort study to investigate the outcomes of hospitalized LC patients with HF and COVID-19 infection, looking at its impact on in-hospital mortality, risk for acute kidney injury (AKI) and length of stay (LOS). We identified a total of 10,810 hospitalized LC patients with HF, of which 1.39 % (n = 150/10,810) had COVID-19 infection. Using a stepwise survey multivariable logistic regression model that adjusted for patient and hospital level confounders, COVID-19 infection among hospitalized LC patients with HF was found to be an independent predictor of overall in-hospital mortality (aOR 3.73; 95 % CI, 1.58-8.79; p = 0.00) and risk for AKI (aOR 3.06; 95 % CI, 1.27-7.37; p = 0.01) compared to those without COVID-19 infection. However, there were comparable rates of LOS among LC patients with HF regardless of COVID-19 infection status. Moreover, AKI was found to be an independent predictor of longer LOS (coefficient 4.40, 95 % CI 3.26-5.38; p = 0.00). On subgroup analysis, diastolic HF was found to be associated with increased risk for in-hospital mortality (aOR 6.54; 95 % CI, 2.02-21.20; p = 0.00), development of AKI (aOR 3.33; 95 % CI, 1.12-9.91; p = 0.03) and longer LOS (coefficient 4.30, 95 % CI 0.79-9.45; p = 0.03). Concomitant COVID-19 infection among hospitalized LC patients with HF was associated with higher risk for in-hospital mortality and AKI but did not significantly affect hospital LOS.
Sections du résumé
Background
UNASSIGNED
There is paucity of data regarding the impact of Coronavirus Disease 2019 (COVID-19) infection on the outcomes of hospitalized liver cirrhosis (LC) patients with heart failure (HF).
Methods
UNASSIGNED
Utilizing the 2020 National Inpatient Sample (NIS) Database, we conducted a retrospective cohort study to investigate the outcomes of hospitalized LC patients with HF and COVID-19 infection, looking at its impact on in-hospital mortality, risk for acute kidney injury (AKI) and length of stay (LOS).
Results
UNASSIGNED
We identified a total of 10,810 hospitalized LC patients with HF, of which 1.39 % (n = 150/10,810) had COVID-19 infection. Using a stepwise survey multivariable logistic regression model that adjusted for patient and hospital level confounders, COVID-19 infection among hospitalized LC patients with HF was found to be an independent predictor of overall in-hospital mortality (aOR 3.73; 95 % CI, 1.58-8.79; p = 0.00) and risk for AKI (aOR 3.06; 95 % CI, 1.27-7.37; p = 0.01) compared to those without COVID-19 infection. However, there were comparable rates of LOS among LC patients with HF regardless of COVID-19 infection status. Moreover, AKI was found to be an independent predictor of longer LOS (coefficient 4.40, 95 % CI 3.26-5.38; p = 0.00). On subgroup analysis, diastolic HF was found to be associated with increased risk for in-hospital mortality (aOR 6.54; 95 % CI, 2.02-21.20; p = 0.00), development of AKI (aOR 3.33; 95 % CI, 1.12-9.91; p = 0.03) and longer LOS (coefficient 4.30, 95 % CI 0.79-9.45; p = 0.03).
Conclusion
UNASSIGNED
Concomitant COVID-19 infection among hospitalized LC patients with HF was associated with higher risk for in-hospital mortality and AKI but did not significantly affect hospital LOS.
Identifiants
pubmed: 36817018
doi: 10.1016/j.ahjo.2023.100271
pii: S2666-6022(23)00023-X
pmc: PMC9916131
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100271Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
ESC Heart Fail. 2019 Jun;6(3):475-486
pubmed: 30829002
Can J Cardiol. 2019 Sep;35(9):1208-1219
pubmed: 31300181
Semin Nephrol. 2011 Nov;31(6):503-12
pubmed: 22099507
N Engl J Med. 2018 Jan 25;378(4):345-353
pubmed: 29365305
Gastroenterology. 2021 Nov;161(5):1487-1501.e5
pubmed: 34284037
SN Compr Clin Med. 2021;3(10):2088-2092
pubmed: 34189405
JACC Heart Fail. 2017 Aug;5(8):578-588
pubmed: 28501521
J Clin Transl Hepatol. 2020 Jun 28;8(2):192-199
pubmed: 32832400
JAMA Cardiol. 2016 Jun 1;1(3):274-81
pubmed: 27438105
Hepatology. 2021 Aug;74(2):1088-1100
pubmed: 33332624
BMC Nephrol. 2018 Oct 23;19(1):292
pubmed: 30352558
Intern Emerg Med. 2020 Apr;15(3):421-428
pubmed: 31686359
Gastroenterol Rep (Oxf). 2017 May;5(2):127-137
pubmed: 28533910
JGH Open. 2020 Dec 14;5(2):199-206
pubmed: 33553656
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Eur J Med Res. 2020 Dec 2;25(1):64
pubmed: 33267871
Crit Care. 2002 Dec;6(6):500-8
pubmed: 12493071
Hepatol Commun. 2020 Jan 21;4(3):453-460
pubmed: 32140661
Eur J Cardiothorac Surg. 2008 Aug;34(2):307-12
pubmed: 18539042
Circulation. 2018 Apr 24;137(17):1814-1823
pubmed: 29352072
Eur J Gastroenterol Hepatol. 2021 Jan;33(1):114-115
pubmed: 32282549
Clin Infect Dis. 2003 May 15;36(10):1259-65
pubmed: 12746771
Gastroenterology. 2020 Aug;159(2):768-771.e3
pubmed: 32376408
Eur J Clin Invest. 2020 Oct;50(10):e13362
pubmed: 32726868
Liver Int. 2020 Oct;40(10):2515-2521
pubmed: 32585065
Int J Mol Sci. 2021 Jul 28;22(15):
pubmed: 34360866
J Am Coll Cardiol. 2020 Nov 17;76(20):2334-2348
pubmed: 33129663
Diabetes Res Clin Pract. 2021 May;175:108794
pubmed: 33831494
Turk J Med Sci. 2020 Apr 17;50(SI-1):620-632
pubmed: 32299202
BMC Med. 2021 Aug 27;19(1):212
pubmed: 34446016
Ann Gastroenterol. 2015 Jan-Mar;28(1):31-40
pubmed: 25608575
J Am Coll Cardiol. 2012 Sep 18;60(12):1031-42
pubmed: 22840531
Biomed Res Int. 2022 Feb 21;2022:4589767
pubmed: 35237687
Eur Heart J. 2018 May 21;39(20):1770-1780
pubmed: 29390051
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Rev Cardiovasc Med. 2021 Sep 24;22(3):925-929
pubmed: 34565092
Clin Med (Lond). 2020 Mar;20(2):146-150
pubmed: 32188648
Circ Heart Fail. 2009 Jul;2(4):370-6
pubmed: 19808361
Cardiol Ther. 2020 Dec;9(2):433-445
pubmed: 32514825
Liver Int. 2020 Jun;40(6):1316-1320
pubmed: 32329563